Rain Oncology Inc. Common Stock
RAIN
RAIN was delisted on the 25th of January, 2024.
62 hedge funds and large institutions have $20M invested in Rain Oncology Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 21 increasing their positions, 7 reducing their positions, and 26 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 7
12% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 26
5% more funds holding
Funds holding: 59 → 62 (+3)
38% less call options, than puts
Call options by funds: $56K | Put options by funds: $91K
89% less capital invested
Capital invested by funds: $184M → $20M (-$164M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$18.7M |
| 2 |
BlackRock
New York
|
+$4.71M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$3.28M |
| 4 |
Millennium Management
New York
|
+$2.78M |
| 5 |
WSL
Western Standard LLC
Los Angeles,
California
|
+$1.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$26M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$18.6M |
| 3 |
PA
Perceptive Advisors
New York
|
-$14.4M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$11.7M |
| 5 |
GC
GMT Capital
Atlanta,
Georgia
|
-$7.21M |
RAIN Hedge Fund Activity: Q2 2023 in Review
62 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Rain Oncology Inc. Common Stock (RAIN) for Q2 2023, worth a combined $20M — down 89% from $184M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new RAIN positions and 26 closed out — a net gain of 3 holders — while 21 added to existing stakes and 7 trimmed.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $18.7M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $26M sold.
- 62 institutional investors held Rain Oncology Inc. Common Stock (RAIN) as of Q2 2023, up from 59 in Q1 2023.
- Funds reported $20M of Rain Oncology Inc. Common Stock stock for Q2 2023, down 89% quarter-over-quarter.
- 29 funds opened new Rain Oncology Inc. Common Stock positions in Q2 2023 and 26 closed out, a net change of +3 holders.
- The largest Rain Oncology Inc. Common Stock buyer in Q2 2023 was Tang Capital Management, an estimated $18.7M added.
- The largest Rain Oncology Inc. Common Stock seller in Q2 2023 was Cormorant Asset Management, an estimated $26M sold.
Based on aggregated 13F filings for Q2 2023.